29 citations
,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
2 citations
,
March 2024 in “Meditsinskiy sovet = Medical Council” JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
2 citations
,
December 2024 in “Journal of Dermatological Treatment” IL-23 inhibitors may help treat other skin conditions, but more research is needed.
80 citations
,
June 2012 in “European Journal of Pharmaceutics and Biopharmaceutics” Nanoparticles improve drug delivery and effectiveness in treating inflamed skin.
17 citations
,
December 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists found new, better-working inhibitors for a hormone-related enzyme.
1 citations
,
August 2025 in “International Journal of Molecular Sciences” Nutraceutical insulin-sensitizing agents may help treat skin conditions like psoriasis and acne.
The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.
19 citations
,
March 2022 in “Journal of Infection” Canakinumab's effect on COVID-19 outcomes is unclear.
1 citations
,
October 2013 in “The American Journal of Gastroenterology” Infliximab can trigger lupus-like symptoms in Crohn's disease patients.
18 citations
,
January 2021 in “Theranostics” The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
Newly designed proteins can effectively degrade specific proteins in cells, offering a potential new therapy method.
17 citations
,
May 2019 in “BMJ Open” JAK/STAT inhibitors show promise for skin diseases but aren't yet approved.
1 citations
,
February 2021 in “Farmacja Polska” Janus kinase inhibitors show promise in treating autoimmune skin diseases.
4 citations
,
December 2024 in “European Journal of Medicinal Chemistry” New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
April 2017 in “Journal of Investigative Dermatology” SIG-1451 could be a promising new treatment for atopic dermatitis.
18 citations
,
August 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Two existing drugs may help treat COVID-19 by inhibiting a key viral protein.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
42 citations
,
January 2019 in “Frontiers in Immunology” A blood pressure drug, diltiazem, may also help treat influenza.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
40 citations
,
December 2016 in “Journal of Dermatological Treatment” JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
277 citations
,
December 2019 in “Frontiers in Immunology” JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.
18 citations
,
August 2024 in “eLife” JAK inhibition may help manage autoimmune conditions in Down syndrome.
278 citations
,
March 2013 in “Gut” Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
27 citations
,
June 2017 in “Expert opinion on investigational drugs” New anti-acne medications are being tested to offer alternatives to current treatments.
9 citations
,
August 2023 in “Molecules” Two peptides, RMYYY and VMYMI, may be effective anti-inflammatory drugs.
May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
Infliximab was effective in treating a scalp condition that did not respond to other treatments.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.